Home LiteratureArticle Details
PMID: 7116690 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Kinetics of interaction of immune complexes with complement receptors on human blood cells: modification of complexes during interaction with red cells.

Clinical and experimental immunology ·Vol. 48 ·No. 3 ·1982-06-00 ·Pages 715-25

Medof ME, Prince GM, Oger JJ

Abstract

Antigen-antibody complexes, composed of 125I-BSA and guinea-pig or rabbit antibody, were incubated at 37 degrees C with human blood cells suspended in autologous serum and kinetics of binding analysed. When purified polymorphonuclear (PMN) or mononuclear cells (MNC) were studied, maximum binding was observed within 8 min, and immune complexes (IC) remained associated with cells even after 1 hr. When cells were studied unseparated (in the same amount of serum), maximum binding was observed slightly earlier (within 4 min), but within 15 min most of the IC were found in the serum. Separation of cell types at the time of maximal binding and studies with cell preparations depleted of different elements revealed that binding was principally to red blood cells (RBC). IC recovered in the serum 16 min after addition to unseparated cells bound very slowly to purified PMN or MNC; binding after 30 min was 10-15% of that observed with fresh IC at 8 min. Ultracentrifugal analysis revealed that reduction in binding efficiency correlated with decrease in the size of IC. RBC isolated after binding and release of IC bound newly-formed IC was identical rapidity and capacity as fresh RBC, indicating that receptors were not altered by IC. Kinetics studies with serum in the absence of cells suggested that interaction with RBC accelerated the rate of change in binding properties of IC. Rates of binding and release were independent of antigen/antibody ratio but were slowed and binding to RBC sustained when diluted or hypocomplementaemic (SLE) serum was substituted for neat serum. Our results suggest that competition for IC by RBC is associated with loss of ability of IC to bind to other blood cell types and reduction in size of IC, and that abnormalities of complement can lead to prolonged association of IC with RBC.

MeSH Terms
Antigen-Antibody Complex/immunology Centrifugation, Density Gradient Erythrocytes/immunology Humans Kinetics Leukocytes/immunology Neutrophils/immunology Receptors, Complement/immunology
Chemicals
Antigen-Antibody Complex Receptors, Complement
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Medof M E
Prince G M
Oger J J
References (19)
19 references, click to expand
  1. Complement dependent immune phagocytosis. I. Requirements for C'1, C'4, C'2, C'3.
    Exp Cell Res. 1968 Jul;51(1):45-67 PMID: 5661952
  2. Human monocytes: distinct receptor sites for the third component of complement and for immunoglobulin G.
    Science. 1968 Dec 13;162(3859):1281-3 PMID: 4177339
  3. C3 inactivator of man. I. Hemolytic measurement by the inactivation of cell-bound C3.
    J Immunol. 1969 Mar;102(3):533-43 PMID: 5813010
  4. C3b inactivator of man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b.
    J Immunol. 1971 Sep;107(3):742-50 PMID: 4999095
  5. The complement system of man. I.
    N Engl J Med. 1972 Sep 7;287(10):489-95 PMID: 4114930
  6. The effects of immune complexes on blood platelets and their relationship to complement activation.
    Immunochemistry. 1972 Nov;9(11):1151-65 PMID: 4263170
  7. Two different complement receptors on human lymphocytes. One specific for C3b and one specific for C3b inactivator-cleaved C3b.
    J Exp Med. 1973 Oct 1;138(4):798-811 PMID: 4542735
  8. Human lymphocytes bear membrane receptors for C3b and C3d.
    J Clin Invest. 1973 Dec;52(12):3239-42 PMID: 4543024
  9. Receptor for soluble C3 and C3b on human lymphoblastoid (RAJI) cells. Properties and biologocal significance.
    J Exp Med. 1974 Mar 1;139(3):696-711 PMID: 4591176
  10. Single-step separation of red blood cells. Granulocytes and mononuclear leukocytes on discontinuous density gradients of Ficoll-Hypaque.
    J Immunol Methods. 1974 Aug;5(3):249-52 PMID: 4427075
  11. A new complement function: solubilization of antigen-antibody aggregates.
    Proc Natl Acad Sci U S A. 1975 Feb;72(2):418-22 PMID: 1054824
  12. Studies on the mechanism of solubilization of immune precipitates by serum.
    J Exp Med. 1976 Mar 1;143(3):615-30 PMID: 1249522
  13. Control of the amplification convertase of complement by the plasma protein beta1H.
    Proc Natl Acad Sci U S A. 1976 Sep;73(9):3268-72 PMID: 1067618
  14. Modulation of the alternative complement pathways by beta 1 H globulin.
    J Exp Med. 1976 Nov 2;144(5):1147-63 PMID: 62817
  15. Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution.
    J Exp Med. 1977 Jul 1;146(1):257-70 PMID: 301546
  16. Genetic polymorphism of murine C3 controlled by a single co-dominant locus on chromosome 17.
    J Immunol. 1978 Aug;121(2):491-8 PMID: 681746
  17. The biochemistry of complement.
    Nature. 1978 Oct 26;275(5682):699-704 PMID: 703835
  18. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.
    Proc Natl Acad Sci U S A. 1979 Nov;76(11):5867-71 PMID: 293688
  19. The immune-adherence phenomenon; an immunologically specific reaction between microorganisms and erythrocytes leading to enhanced phagocytosis.
    Science. 1953 Dec 18;118(3077):733-7 PMID: 13122009
Article Info
Journal
Clinical and experimental immunology
Abbr.
Clin Exp Immunol
ISSN
0009-9104
Published
1982-06-00
Pages
715-25
Language
English
Region
England
NLM ID
0057202
PMCID
PMC1536626
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]